Exelixis Inc (EXEL)
NASDAQ · Healthcare · Biotechnology
Exelixis Inc is a Healthcare company with a market capitalization of $12.80B and a trailing P/E ratio of 16.3.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $0.87 | $0.76 | +14.5% |
| Q4 2025 | February 10, 2026 | $0.94 | $0.81 | +16.1% |
| Q3 2025 | November 4, 2025 | $0.78 | $0.67 | +16.4% |
| Q2 2025 | July 28, 2025 | $0.75 | $0.65 | +15.4% |
| Q1 2025 | May 13, 2025 | $0.62 | $0.37 | +69.1% |
| Q4 2024 | February 11, 2025 | $0.55 | $0.49 | +12.2% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 30,913,414 | 11.56% | 12.7 | +8.3% |
| June 30, 2026 | 28,539,118 | 10.68% | 8.6 | -6.8% |
| June 15, 2026 | 30,635,016 | 11.46% | 13.5 | +3.1% |
| May 29, 2026 | 29,707,071 | 11.11% | 12.4 | -1.9% |
| May 15, 2026 | 30,278,606 | 11.33% | 9.2 | +0.9% |
| April 30, 2026 | 30,010,146 | 10.65% | 12.6 | +6.0% |
| April 15, 2026 | 28,306,926 | 10.04% | 13.1 | +3.8% |
| March 31, 2026 | 27,263,165 | 9.67% | 11.0 | +3.5% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Exelixis Inc's market cap?
As of August 13, 2026, Exelixis Inc (EXEL) has a market capitalization of $12.80B.
What is Exelixis Inc's P/E ratio?
Exelixis Inc trades at a trailing price-to-earnings (P/E) ratio of 16.3. Its forward P/E is 16.3.
Does Exelixis Inc pay a dividend?
Exelixis Inc does not currently pay a dividend.
What sector is EXEL in?
Exelixis Inc is in the Healthcare sector, specifically the Biotechnology industry.
What is Exelixis Inc's short interest?
As of the July 15, 2026 FINRA settlement, 30,913,414 EXEL shares were sold short, or 11.56% of shares outstanding. Days to cover: 12.7. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Exelixis Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Exelixis Inc reported revenue of $2.32B and net income of $782.57M.
Ask your own questions about EXEL
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.